Outcome of Prophylactic Therapy with LMWH and Aspirin in Pregnancy with Antiphospholipid Syndrome
DOI:
https://doi.org/10.51985/Keywords:
Keyword; Antiphospholipid syndrome (APS), Aspirin , Low Molecular Weight Heprin (LMWH)Abstract
Objective:To determine the fetal outcome after prophylactic therapy with low molecular weight hepain and aspirin in pregnant woman with recurrent pregnancy loss (antiphosholipid syndrome)
Study Design and Setting: This is retrospective observational study conducted in Department of obstetrics and gynecology at Indus hospital Karachi from 20 December 2016 to 30 September2022.
Methodology; The study group include 39 pregnant woman with antiphophospholipd syndrome (recurrent pregnancy loss) presented at Sheikh Saeed campus of Indus Hospital Karachi from 2016 to 2022. Patients were diagnosed with APLS on the basis of Sapporo clinical criteria for aPLS. All these patients were treated with prophylactic therapy with aspirin and low molecular weight heparin throughout pregnancy. The primary outcome was live birth. Statistical analysis was done through SPSS version 26.
Result: Prophylactic therapy with low molecular weight heparin and aspirin in pregnant woman with recurrent pregnancy loss has a significant impact on the fetal outcome. 79.5% delivered alive babies. 12.8 % experienced miscarriage. 2.6 % had termination of pregnancy due to congenital malformation. 5.2% were unable to follow-up.
Conclusion; Prophylactic therapy with low molecular weight heparin and aspirin has significantly improved live birth rate (79.5%) in patients with recurrent pregnancy loss with antiphospholipid syndrome.
References
1. Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernández
OM, Gaybor M, Cordero C, Cabrera S, Soroka NF. Obstetric
antiphospholipid syndrome. Autoimmun Rev. 2012
Feb;11(4):288-95. doi: 10.1016/j.autrev.2011.10.006. Epub
2011 Oct 7. PMID: 22001418
2. Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis
and management of the antiphospholipid syndrome. BMJ
2010;340:1125–32. BMJ. 2010 May 14;340:c2541. doi:
10.1136/ bmj.c2541. PMID: 20472677.
3. Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospohlipid
syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol.
2012 Feb;26(1):65-76. doi: 10.1016/j.bpobgyn.2011.10.006.
Epub 2011 Nov 11. PMID: 22079775.
4. Rai RS, Clifford K, Cohen H, Regan L. High prospective
fetal loss rate in untreated pregnancies of women with recurrent
miscarriage and antiphospholipid antibodies. Hum Reprod.
1995 Dec;10(12):3301-4. doi: 10.1093/oxfordjournals.
humrep.a135907. PMID: 8822463
5. . Tuthill JI, Khamashta MA. Management of antiphospholipid
syndrome. J Autoimmun. 2009 Sep;33(2):92-8. doi: 10.1016/
j.jaut.2009.05.002. Epub 2009 Jun 25. PMID: 19559568.
6. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent
miscarriage for women with antiphospholipid antibody or
lupus anticoagulant. Cochrane Database Syst Rev. 2005 Apr
18;2005(2):CD002859. doi: 10.1002/14651858.
CD002859.pub2. PMID: 15846641; PMCID: PMC67689877. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL,
Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL,
Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG,
Krilis SA. International consensus statement on an update of
the classification criteria for definite antiphospholipid syndrome
(APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi:
10.1111/j.1538-7836.2006.01753.x. PMID: 16420554.
8. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche
A, Renaer M. Decidual vasculopathy and extensive placental
infarction in a patient with repeated thromboembolic accidents,
recurrent fetal loss, and a lupus anticoagulant. Am J Obstet
Gynecol. 1982 Apr 1;142(7):829-34. doi: 10.1016/s0002-
9378(16)32527-3. PMID: 6801984
9. Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga
N, Ohta K, Yasuda S, Koike T, Minakami H. Antiphospholipid
antibodies increase the risk of pregnancy-induced hypertension
and adverse pregnancy outcomes. J Reprod Immunol. 2009
Jan;79(2):188-95. doi: 10.1016/j.jri.2008.11.001. Epub 2009
Feb 10. PMID: 19211151
10. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K.
The association of antiphospholipid antibodies with
pregnancies complicated by fetal growth restriction. Obstet
Gynecol. 1991 Dec;78(6):1108-11. PMID: 1945217.
11. Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta
MA, Hunt BJ, Poston L. The placental bed in pregnancies
complicated by primary antiphospholipid syndrome. Placenta.
2006 Apr-May;27(4-5):457-67. doi: 10.1016/j.placenta.
2005.04.006. Epub 2005 Jul 6. PMID: 16005063
12. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod
Immunol. 2002 May-Jun;55(1-2):163-80. doi: 10.1016/s0165-
0378(01)00144-9. PMID: 12062831.
13. Laklouk, Mahmoud; Elshikha, Khaled; and Ellaban, Mostafa
(2022) "Timing of initiation of low molecular weight Heparin
and Aspirin administration on the pregnancy outcome in
women with Antiphospholipid syndrome and recurrent abortion
," Al-Azhar International Medical Journal: Vol. 3: Iss. 9,
Article 15. DOI: https://doi.org/10.21608/ aimj.2022.129650.
1883
14. Hamulyák EN, Scheres LJ, Marijnen MC, Goddijn M,
Middeldorp S. Aspirin or heparin or both for improving
pregnancy outcomes in women with persistent antiphospholipid
antibodies and recurrent pregnancy loss. Cochrane Database
Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/
14651858.CD012852.pub2. PMID: 32358837; PMCID:
PMC7195627.
15. Yu X, He L. Aspirin and heparin in the treatment of recurrent
spontaneous abortion associated with antiphospholipid antibody
syndrome: A systematic review and meta-analysis. Exp Ther
Med. 2021 Jan;21(1):57. doi: 10.3892/etm.2020.9489. Epub
2020 Nov 19. PMID: 33365057; PMCID: PMC7716630.
16. Juneja, S. K., Tandon, P., Kaur, G., Kapoor, B., & Sidhu, G.
S. (2020). Comparison of empirical use of low dose aspirin
and enoxaprin in the treatment of unexplained recurrent
pregnancy loss. International Journal of Reproduction,
Contraception, Obstetrics and Gynecology, 9(3), 1138–1142.
https://doi.org/10.18203/2320-1770.ijrcog20200889
17. Rekha, S. B., & Chandra, K. S. (2020). Comparative study
of low dose aspirin versus combination of low dose aspirin
and low molecular weight heparin in idiopathic recurrent
pregnancy loss. International Journal of Reproduction,
Contraception, Obstetrics and Gynecology, 9(2), 512–515.
https://doi.org/10.18203/2320-1770.ijrcog2020001018. Manisha M. Laddad, N. S. Kshirsagar, Sanjaykumar P. Patil,
Gauri Shinde, Pranjal Nimbalkar. “Low Dose Aspirin in
Combination with Low-Molecular-Weight Heparin is better
than Low Dose Aspirin Alone in the Treatment of Pregnant
Women with Recurrent Miscarriages”. Journal of Evolution
of Medical and Dental Sciences 2014; Vol. 3, Issue 21, May
26; Page: 5753-5760, DOI: 10.14260/jemds/2014/2660
19. Jeremiæ K, Pervulov M, Gojniæ M, Dukanac J, Ljubiæ A,
Stojniæ J. Comparison of two therapeutic protocols in patients
with antiphospholipid antibodies and recurrent miscarriages.
Vojnosanit Pregl. 2005 Jun;62(6):435-9. doi:
10.2298/vsp0506435j. PMID: 16047856.
20. Mo D, Saravelos S, Metwally M, Makris M, Li TC. Treatment
of recurrent miscarriage and antiphospholipid syndrome with
low-dose enoxaparin and aspirin. Reprod Biomed Online.
2009 Aug;19(2):216-20. doi: 10.1016/s1472-6483(10)60075-
2. PMID: 19712557.
21. Tanimura K, Saito S, Tsuda S, Ono Y,Deguchi M, Nagamatsu
T, Fujii T,Nakatsuka M, Kobashi G, Arase H andYamada H
(2024) Low-dose aspirin and heparin treatment improves
pregnancy outcome in recurrent pregnancy loss women with
antib2glycoproteinI/HLA-DR autoantibodies: a
prospective,multicenter, observational study.Front. Immunol.
15:1445852. doi: 10.3389/fimmu.2024
22. Mercier, M.; Lescoat, A.;Pierre-Jean, M.; Dumontet, E.; Le
Lous, M.; Belhomme, N. Prevalence of Antiphospholipid
Antibody Syndrome Among Patients with Recurrent Pregnancy
Loss: Impact of the Revised 2023 ACR/EULAR
Antiphospholipid Syndrome Criteria. J. Clin. Med. 2024, 13,
7698. https://doi.org/10.3390/ jcm1324769
23. Barbhaiya M, et al. Ann Rheum Dis 2023;82:1258–1270.
doi:10.1136/ard-2023-224609
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
